Genmab A/S (0MGB.IL)

2.052,00 +107,75 (+5,54%) Alla chiusura: 06:43PM BST

Genmab A/S

Kalvebod Brygge 43
Copenhagen 1560
Denmark
45 70 20 27 28
https://www.genmab.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 2.015

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Jan G.J. van de Winkel Ph.D.	Co-Founder, Pres & CEO	18,8M	N/D	1961
Mr. Anthony Pagano	Exec. VP & CFO	7M	N/D	1978
Mr. Anthony Mancini	Exec. VP & COO	7,6M	N/D	1971
Mr. Martin Schultz	Sr. Director of Clinical Operations & Non-Independent Director	500k	N/D	1976
Dr. Judith V. Klimovsky M.D.	Exec. VP & Chief Devel. Officer	7,9M	N/D	1958
Dr. Tahamtan Ahmadi	Exec. VP, Chief Medical Officer & Head of Experimental Medicines	7,5M	N/D	1973
Dr. Mijke Zachariasse Ph.D.	Sr. Director, Head of Antibody Research Materials & Non-Independent Director	1M	N/D	1974
Mr. Takahiro Hamatani	Sr. Director of Fin. Japan & Non-Independent Director	500k	N/D	1975
Mr. Andrew Carlsen	Sr. Director, VP & Head of Investor Relations	N/D	N/D	N/D
Ms. Birgitte Stephensen M.Sc.	Exec. VP & Chief Legal Officer	N/D	N/D	1961

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in DKK.

Descrizione

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Governance aziendale

L'ISS Governance QualityScore di Genmab A/S al 1 ottobre 2023 è 4. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 1; diritti degli azionisti: 1; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.